The MPS I market is advancing through enzyme replacement therapies and novel treatment approaches. Key players including Sanofi, Takeda, and BioMarin are developing advanced therapeutics and gene therapies that improve clinical outcomes and quality of life. Enhanced newborn screening and treatment guidelines are enabling earlier intervention and better disease management for this rare lysosomal storage disorder. Access Market Report: https://shorturl.at/nNxbj